GLP1R and heart failure: Compared to the efficacy of SGLT2 inhibitors on hospitalisation for heart failure in DAPA-HF [11, 27] (2-year meta-number needed to treat of 21) and EMPEROR-REDUCED [12, 27] (2-year meta-number needed to treat of 15), the present analysis revealed only moderate absolute beneficial treatment effects of GLP-1 receptor agonists (36-month meta-number needed to treat of 85) and SGLT2 inhibitors (36-month meta-number needed to treat of 104) for a composite renal outcome.